[UFT concentration in serum and tissues of patients with gynecologic malignant tumors following oral administration]. 1985

S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura

Oral UFT was given to patients with genital carcinoma prior to surgery. 5-FU, FT and uracil levels in the tumor site were then measured in the surgical specimens obtained. Simultaneous estimates of tissues and plasma 5-FU indicated that the amount of drug in the tumor site (0.227 +/- 0.117 micrograms/g wet weight) had a 6.3-fold increase in concentration compared with that in normal tissues (0.036 +/- 0.019 micrograms/g wet weight) and was approximately 13.4 times that of the peripheral circulation (0.017 +/- 0.007 micrograms/ml). The rate of increase in concentration of tissue 5-FU rose especially in carcinoma of the cervix (0.394 +/- 0.215 micrograms/g), corpus uteri (0.116 +/- 0.042 micrograms/g) and ovary (0.171 +/- 0.047 micrograms/g). In the case of carcinoma of the cervix, the concentration of 5-FU in the tumor site was found to be about 14.1 times higher in invasive carcinoma than in carcinoma in situ. 5-FU concentration in the tumor site showed a still higher level compared with normal tissue after the drug was administered, suggesting an accumulation of 5-FU within the tumor.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005833 Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). Gynecologic Neoplasms,Female Genital Neoplasms,Neoplasms, Female Genital,Neoplasms, Gynecologic,Female Genital Neoplasm,Genital Neoplasm, Female,Gynecologic Neoplasm,Neoplasm, Female Genital,Neoplasm, Gynecologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
July 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
August 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
November 1986, Gan no rinsho. Japan journal of cancer clinics,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
August 1984, Nihon Sanka Fujinka Gakkai zasshi,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
October 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
November 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
October 1986, Hinyokika kiyo. Acta urologica Japonica,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
July 1991, Hinyokika kiyo. Acta urologica Japonica,
S Inoue, and S Shibata, and A Okumura, and T Tanaka, and Y Onitsuka, and T Yoshimura, and A Aiko, and Y Ikuta, and K Fukuma, and K Matsuura
March 1974, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Copied contents to your clipboard!